FutureChem (220100) closed at the upper price limit on the KOSDAQ market on the 23rd. In the regular session, the stock finished at 8,990 won, up 2,070 won (29.91%) from the previous trading day, drawing investors' attention by rising to the daily price limit in Friday's session ahead of the weekend.

That day, FutureChem disclosed the key results of a clinical trial for its prostate cancer treatment.

■ Disclosure of Receipt of Clinical Topline Data

FutureChem announced that it received the key results (topline data) of its Phase 2a clinical trial of the radiopharmaceutical candidate '[177Lu]Ludotadapep' conducted in the United States in patients with metastatic castration-resistant prostate cancer (mCRPC).

■ Key Efficacy Figures

According to the disclosure, the objective response rate (ORR), the primary endpoint of the trial, was 38.89%. Complete or partial responses were confirmed in 7 of the 18 evaluable subjects.

Specifically, complete response (CR) was recorded in 5 patients, or 27.78%, and partial response (PR) in 2 patients, or 11.11%. The disease control rate (DCR), a secondary efficacy endpoint, was tallied at 83.33% (15 of 18 patients). The PSA response rate, defined as the proportion of patients whose prostate-specific antigen (PSA) levels fell by 50% or more from baseline, came in at 58.82% (10 of 17 patients).

■ Future Schedule and Remaining Challenges

The company plans to conduct further analysis of the detailed data and receive the clinical study report (CSR) within this year. Data collection is continuing for items requiring long-term follow-up, such as safety and survival rates.

However, these results do not imply final product approval. It should be noted that uncertainties remain in future analyses and the approval process.

■ Focus on Next Trading Day, the 26th

Whether the upward momentum can continue on the next trading day after the limit-up close is a key point to watch. Given the sharp short-term surge in the stock price, the possibility of profit-taking sell orders also needs to be considered.

With attention focused on how FutureChem's clinical trial results will affect its future new drug development timeline and commercialization efforts, all eyes are on whether FutureChem, which ended the week's trading at the limit-up price, can sustain its strength on the next trading day, the 26th.

[This article is not intended to solicit investment, and the final judgment and responsibility for investments rest with the investor.]